Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

氯替泼诺混悬滴眼液 - NMPA Drug Approval Details

Approvals/NMPA/Loteprednol Etabonate Ophthalmic Suspension

Approved

化学药品

Loteprednol Etabonate Ophthalmic Suspension

Bausch & Lomb Incorporated🇨🇳 National Medical Products Administration

Approval Date: May 11, 2023
Approval ID: 1yQCMPtkbgU
Company: Bausch & Lomb Incorporated
Type: 化学药品

Approval Details

Approval Id: 1yQCMPtkbgU
Approval Number: 国药准字HJ20180059
Generic Name: 氯替泼诺混悬滴眼液
Generic Name En: Loteprednol Etabonate Ophthalmic Suspension
Drug Type: 化学药品
Dosage Form: 眼用制剂
Strength: 0.2%(5ml:10mg;10ml:20mg)
Reg Date: 2023-05-11
Expired Date: 2028-03-28
Company Name: Bausch & Lomb Incorporated
Production Company Name: Bausch & Lomb Incorporated
Company Detail Path: /organization/bausch-and-lomb-incorporated
Production Company Detail Path: /organization/bausch-and-lomb-incorporated

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

May 11, 2023

Approval ID

1yQCMPtkbgU

Type

化学药品

Back to NMPA Approvals